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Background: Modelling the blood-CNS barriers of the brain and spinal cord in vitro continues to provide a
considerable challenge for research studying the passage of large and small molecules in and out of the central
nervous system, both within the context of basic biology and for pharmaceutical drug discovery. Although there
has been considerable success over the previous two decades in establishing useful in vitro primary endothelial cell
cultures from the blood-CNS barriers, no model fully mimics the high electrical resistance, low paracellular
permeability and selective influx/efflux characteristics of the in vivo situation. Furthermore, such primary-derived
cultures are typically labour-intensive and generate low yields of cells, limiting scope for experimental work. We
thus aimed to establish protocols for the high yield isolation and culture of endothelial cells from both rat brain
and spinal cord. Our aim was to optimise in vitro conditions for inducing phenotypic characteristics in these cells
that were reminiscent of the in vivo situation, such that they developed into tight endothelial barriers suitable for
performing investigative biology and permeability studies.
Methods: Brain and spinal cord tissue was taken from the same rats and used to specifically isolate endothelial
cells to reconstitute as in vitro blood-CNS barrier models. Isolated endothelial cells were cultured to expand the
cellular yield and then passaged onto cell culture inserts for further investigation. Cell culture conditions were
optimised using commercially available reagents and the resulting barrier-forming endothelial monolayers were
characterised by functional permeability experiments and in vitro phenotyping by immunocytochemistry and
western blotting.
Results: Using a combination of modified handling techniques and cell culture conditions, we have established
and optimised a protocol for the in vitro culture of brain and, for the first time in rat, spinal cord endothelial cells.
High yields of both CNS endothelial cell types can be obtained, and these can be passaged onto large numbers of
cell culture inserts for in vitro permeability studies. The passaged brain and spinal cord endothelial cells are pure
and express endothelial markers, tight junction proteins and intracellular transport machinery. Further, both models
exhibit tight, functional barrier characteristics that are discriminating against large and small molecules in
permeability assays and show functional expression of the pharmaceutically important P-gp efflux transporter.
Conclusions: Our techniques allow the provision of high yields of robust sister cultures of endothelial cells that
accurately model the blood-CNS barriers in vitro. These models are ideally suited for use in studying the biology of
the blood-brain barrier and blood-spinal cord barrier in vitro and for pre-clinical drug discovery.
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The endothelial blood-CNS barriers, located at the
microvascular cells of the brain and spinal cord, repre-
sent the crucial interface between the maelstrom of the
peripheral circulation and the tightly regulated environ-
ment of the central nervous system (CNS). Here, the
blood–brain barrier (BBB) and blood-spinal cord barrier
(BSCB) present a formidable structural and metabolic
barrier that partitions the CNS parenchyma. Far from
being impenetrable blockades, the blood-CNS barriers
are highly dynamic regulatory interfaces that apply strict
control over the passage of blood-borne substances into
the CNS, and oversee regulated transport of large and
small molecules back into the periphery. The blood-
CNS barriers are of great relevance to pharmaceutical
drug discovery, as the BBB and BSCB present obstacles
to the delivery of compounds aimed at the treatment of
CNS disorders affecting the brain and spinal cord. A
fuller understanding of each of these barriers will aid the
development of CNS-targeted small and large molecule
therapies to treat wide-ranging and devastating neuro-
logical diseases, from neurodegeneration to chronic pain
[1-4]. To facilitate basic research and drug discovery, it
is therefore highly desirable to have robust and conveni-
ent in vitro models of the BBB and BSCB, from species
relevant for pre-clinical investigations [1,5]. Such models
must aim to faithfully recreate the exquisite in vivo tis-
sue microenvironment that induces a blood-barrier
phenotype. For the BBB, as well as the more poorly
understood BSCB, this has posed a considerable tech-
nical challenge. The goal for in vitro BBB and BSCB
model development is to obtain convenient primary cell
cultures that can be easily and inexpensively established
and possess robust barrier phenotypes similar to those
seen in vivo. Good in vitro barriers will possess proper-
ties such as high transendothelial electrical resistance
(TEER) across the endothelial monolayer and low pas-
sive, non-specific paracellular permeability to small and
large molecules such as Lucifer yellow (LY), hydropho-
bic compounds and FITC-labelled dextrans. For a truly
representative model, other features such as expression
of receptors and transporters on the endothelial cell
surface and intracellular transcytosis machinery must
be maintained to allow transcellular transport pathways
for ions, small molecules, peptides and proteins to
be reconstituted in vitro. An additional problem for
establishing robust in vitro blood-CNS barrier models
is the provision of sufficient numbers of cells to allow
for rigorous characterisation of the models and investi-
gative biology or drug screening. The typically low
yields of endothelial cells can severely limit research ef-
forts, particularly for tissues such as the spinal cord
where the amount of tissue recovered per animal is
especially low.The fundamental features of the blood-CNS barriers
in vivo are well known but difficult to fully replicate
in vitro. These barrier-forming elements include highly
developed endothelial tight junctions that lead to high
TEER, lack of endothelial fenestrae, low non-specific
pinocytosis and the expression of receptors and trans-
porters that facilitate small and large molecule influx
and efflux [6]. One of the greatest hurdles to translating
these in vivo features into robust in vitro models is
that the development of the in vivo CNS-blood barrier
phenotype is exquisitely regulated by the cellular micro-
environment of the brain and spinal cord endothelial
cells. Astrocytes have long been demonstrated to induce
barrier function at the BBB in vitro and in vivo [7] and
increasing evidence is pointing to a similarly important
role for pericytes in barrier development and mainten-
ance [8-12]. In spite of these challenges, in vitro model-
ling of the BBB, and to a lesser extent the BSCB, has
progressed significantly over the previous two decades.
BBB primary endothelial cell culture models have been
established with cells isolated from human [13-19],
mouse [20-26], rat [16,27-35], bovine [36-43] and pig
[44-54] brain tissues. BSCB endothelial models have, in
contrast, currently only been described in vitro for a sin-
gle species, namely mouse [55]. BBB in vitro primary cell
culture barrier models have progressed from simple
solo-cultures of brain endothelial cells to more complex
co-culture models in which endothelial cells are grown
on porous cell culture inserts and co-cultured with post-
natal rodent astrocytes [7]. Astrocytes may be plated ei-
ther into the bottom of a multi-well dish into which the
insert is placed or grown on the underside of the insert it-
self in so-called back-to-back contact co-culture models.
Recently, increasingly complex co-culture models, such as
triple cultures of endothelial cells with astrocytes and
pericytes [10-12] have been developed. However, although
these models display good barrier phenotypes in vitro,
they are particularly labour-intensive and expensive to es-
tablish. It has also been demonstrated that neural stem
cells have the ability to induce barrier properties in vitro
in a manner which may be representative of BBB develop-
ment in vivo [56,57]. Further improvements to barrier
phenotype have been demonstrated through the manipu-
lation of cell culture conditions. It has been known
for several years that factors such as modulators of
intracellular cAMP signalling [58,59], glucocortocoids
[22,26,53,60,61] and growth factors such as bFGF [62,63]
can induce improvements in barrier phenotype in cultured
primary brain endothelial cells. Other manipulations, such
as modulating the buffering capacity of cell culture
medium [64] and optimising endothelial cell seeding dens-
ity [23,31] can influence and improve barrier function. In
recent years, the inclusion of puromycin as a method for
removing contaminating non-endothelial cells has become
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protocols [27,31,51,61,65].
There continues to be a need, however, to evolve blood-
CNS barrier modelling techniques to achieve increasingly
representative in vitro phenotypes that faithfully recapitu-
late the tight, discriminative situation found in brain and
spinal cord capillaries in vivo. The reproducibility of BBB
cell culture models can be inconsistent from week-to
-week or lab-to-lab, and thus for routine use in academic
and pharmaceutical studies it is highly desirable to have
protocols that produce robust and reliable in vitro barriers.
Additionally, it is also highly useful to have such in vitro
blood-CNS barrier models from commonly used pre-
clinical species, such as the rat, so that in vitro data is rele-
vant to the in vivo models employed during early CNS
drug discovery efforts. Such representative in vitro models
may then be employed to characterise drug toxicity and
permeability early in pharmaceutical development and
thus have great potential for contributing to a reduction in
the high attrition rate of drugs in early development for
CNS diseases.
We set out to investigate whether an easy and highly
robust protocol could be established that allowed the
production of large numbers of brain and, for the first
time in rat, spinal cord endothelial cells from a minimal
amount of starting tissue. The aim was to obtain high
yields of cells that could be passaged onto cell culture
inserts and induced to form tight monolayer barriers for
permeability studies. By optimizing culture conditions
using specific handling techniques and commercially
available reagents, we have demonstrated the isolation
and culture of large numbers of both types of endothe-
lial cell, from the same animals. These barrier cultures
are pure endothelial in nature, show correct localisation
of tight junction proteins, have discriminating barrier
characteristics and restrict the paracellular permeability
of large and small molecules. We thus present a further
evolution in the techniques for establishing in vitro blood-
CNS barriers in a relevant pre-clinical species. These
models have utility for investigation of the basic biology of
the BBB and BSCB in vitro and in CNS-focused pharma-
ceutical drug development and toxicity studies.Methods
Materials
All tissue culture media, supplements and reagents are
from Gibco, Life Technologies UK, unless otherwise
stated. All compounds and reagents are from Sigma-
Aldrich, UK unless otherwise stated.Isolation of rat brain microvascular endothelial cells
All procedures were carried out in accordance with the
Animals (Scientific Procedures) Act, 1986. Four maleWister rats (200–250 grams, Charles River, UK) were
euthanized humanely and whole brains removed and
stored in HBSS buffer (calcium/magnesium-free, plus
10 mM HEPES, penicillin/streptomycin) on ice. Under
aseptic conditions, the brain stem and cerebellum was
dissected and each brain was cut in half sagitally. The
mid-brain white matter and the choroid plexus were
removed and the remaining cortical tissue rolled on dry
Whatmann paper to remove the meninges. The meninges-
free cortical tissue was transferred into ice-cold isolation
buffer (HBSS plus calcium and magnesium, 10 mM
HEPES, 0.1% BSA) and homogenised on ice using a 15 mL
Dounce homogeniser with 20 strokes of the loose pestle
followed by 10 strokes of the tight pestle. Following each
homogenisation, the pestle was washed with isolation
buffer to recover as much brain tissue as possible. The
brain homogenate was pelleted by centrifugation at 240 × g
for five minutes at 4°C. The supernatant was aspirated and
the pellet resuspended in pre-warmed digestion mix,
containing 1 mg/mL collagenase/dispase (Roche, UK),
10 μg/mL DNAse I (Roche, UK) and 0.147 μg/mL tosyl-
lysine-chloromethylketone (TLCK). The tissue/digestion
mix was incubated at 37°C for 30 minutes with gentle
shaking. Digested tissue was pelleted by centrifugation at
240 × g for five minutes at 4°C and the pellet was
resuspended in 22% (w/v) bovine serum albumin (First-
Link, UK) by shaking vigorously. Centrifugation at 1500 ×
g for 15 minutes at 4°C resulted in a pellet containing
microvessels, with a buoyant layer of myelin floating at the
top. The myelin/BSA fraction was poured off, re-mixed
and centrifuged again. The microvessel pellet was
resuspended in isolation buffer and stored on ice. The
process was repeated for a total of four centrifugations and
the resuspended microvessels were pooled and pelleted by
centrifugation at 240 × g for five minutes at 4°C. The
supernatant was aspirated and the microvessel pellet was
resuspended in pre-warmed digestion mix, followed by
incubation at 37°C for 15 minutes with gentle shaking.
After digestion, the microvessel fragments were pelleted by
centrifugation at 240 × g for five minutes at 4°C and washed
once in serum-containing cell culture medium to remove
traces of enzyme. The resulting microvessel fragments were
resuspended in DMEM (phenol red-free, supplemented
with 15% plasma-derived serum [PDS, First-Link, UK], glu-
tamine, BME vitamins (Sigma), antibiotic/antimycotic sup-
plement, 200 μM ascorbic acid, 3 μM puromycin and 1×
microvascular growth supplement [MVGS, Life Technolo-
gies]), and plated in eight wells over two 6-well plates pre-
coated with 10 μg/cm2 collagen I (BD Biosciences) and
5 μg/cm2 fibronectin. The commercial MVGS supplement
contains foetal bovine serum, hydrocortisone, human FGF,
heparin, human EGF and dibutyryl cyclic AMP. Culture
medium was replaced after 2–3 days in vitro (DIV) for
identical medium, without ascorbic acid. Puromycin was
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culture to maintain selective pressure on the barrier-
forming endothelial cells and to minimise the growth of
any non-endothelial cells prior to passaging (Figure 1).
Isolation of rat spinal cord endothelial cells
Spinal cords were removed from the same animals as brain
tissue was taken from, and stored separately in HBSS buf-
fer (calcium/magnesium-free, plus 10 mM HEPES, penicil-
lin/streptomycin) on ice. Under aseptic conditions, the
outer membranes were removed and the spinal cord tissue
was chopped using sterile scissors into a uniform suspen-
sion. The spinal cord tissue suspension was transferred
into isolation buffer on ice and pooled. Following this step,
spinal cord tissue was processed in the same manner as
brain tissue from the first enzymatic digestion as described
above. The resulting microvessel fragments were
resuspended in plating media and plated in two wells of
one 6-well plate pre-coated with 10 μg/cm2 collagen I and
5 μg/cm2 fibronectin.
Preparation of rat mixed glial feeder layer
Mixed glial cells were prepared using a protocol based
on the method of McCarthy and de Vellis [66]. Ten
Wistar rat pups at postnatal day 0–2 (Charles River,
UK) were decapitated and whole brains removed and
placed in chilled, serum-free DMEM on ice. From each
brain, both cortices were removed with a sterile scalpel
blade and then rolled on dry, sterile Whatmann filterFigure 1 Culture and passaging schedule for rat brain and spinal cord
for cell culture inserts and tissue culture dishes are suggested for each cellpaper to remove the meninges. Pooled cortical tissue
was pressed through a 70 μm cell strainer (BD Falcon)
to give a homogeneous cell suspension. The cell suspen-
sion was pooled and centrifuged at 240 × g for five mi-
nutes. The resulting pellet was resuspended in 100 mL
of glial maintenance media (DMEM supplemented with
10% FBS, glutamine and penicillin/streptomycin) and
plated out into 10 × T75 flasks, 10 mL per flask. The cell
suspension was cultured undisturbed for 1 week (37°C,
5% CO2) before a full media change to remove non-
adherent cell debris. The proliferating mixed glial prep-
aration was cultured for a further 14 days to allow
growth, with a full media change after 7 days. After a
total of 21 days in culture, the mixed glia were passaged
with 0.25% trypsin:EDTA, resuspended in astrocyte
freezing medium (DMEM, 10% FBS, 10% DMSO) at a
concentration of 2–3 million cells/mL and frozen at a
rate of 1°C/min at −80°C using a Nalgene freezing con-
tainer. For establishing mixed glial feeder layers for co-
culture with endothelial cells, single vials of frozen
mixed glia were quickly thawed in a 37°C water bath and
added drop-wise to 50 mL pre-warmed (37°C) glial main-
tenance media. Cells were pelleted at 240 × g for five mi-
nutes and resuspended in 5 mL glial maintenance media
before plating in a single T25 flask. Mixed glial cells were
grown to 95% confluence before passage with 0.25% tryp-
sin: EDTA and seeding into 24-well plates at least 3 days
before cell culture inserts with endothelial cells were
added to the 24-well plate.endothelial cells with mixed glial cells. Maximum plating densities
type.
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cells onto cell culture inserts and tissue culture plates
Rat brain or spinal cord endothelial cells grown on col-
lagen I/fibronectin-coated plates were passaged at ~95%
confluence. Cells were washed twice with pre-warmed
PBS and 400 μL of pre-warmed 0.25% trypsin was added
to each well. The plates were immediately returned to a
37°C incubator for four minutes. The trypsinisation
was stopped by adding 1 mL of cell culture medium
containing 15% PDS to each well. The endothelial cells
were washed off and resuspended by gently pipetting up
and down. Cells were split at a ~1:1 ratio, on a surface
area basis. For example, the 9.5 cm2 of a single well on a
6-well plate could cover the equivalent of 28 × 24-well
cell culture inserts each with a surface area of 0.33 cm2
(Figure 1). Cells were resuspended in either DMEM/
MVGS (phenol red-free DMEM supplemented with 20%
PDS, glutamine, BME vitamins, antibiotic/antimycotic
supplement and 1× MVGS) or EBM-2/EGM-2 (EBM-2
media plus 15% PDS, glutamine, BME vitamins, BulletKit
SingleQuots minus the human recombinant VEGF sup-
plement [recombinant human FGF, recombinant human
EGF, recombinant human IGF, hydrocortisone, GA-1000,
ascorbic acid], all Lonza, UK) media formulations. The
MVGS supplement does not contain VEGF, a factor
known to increase permeability across brain endothelial
cell monolayers [52], and so this factor was not added
from the EGM-2 BulletKit. The resuspended cells at the
adjusted concentration were plated in the upper chambers
of cell culture inserts in the 24-well format at 200 μL/well
(Millipore, PET, 1.0 μm pore size). Pre-seeded mixed glial
cells were switched from astrocyte maintenance medium
into 1 mL DMEM/MVGS or EBM-2/EGM-2 and the in-
serts with endothelial cells were added. Brain and spinal
cord endothelial cells and astrocytes were cultured for a
further 7–14 days, with media changes every 2–3 days.
Measurement of transendothelial electrical resistance
Cells cultured on inserts in 24-well plates were removed
from the tissue culture incubator (37°C, 5% CO2), and
allowed to equilibrate to room temperature for 20 mi-
nutes. TEER values were measured using an EVOM2
voltometer with STX-2 electrodes (World Precision In-
struments). To calculate TEER (Ω (Ohms) × cm2), elec-
trical resistance across a collagen I/fibronectin-coated
insert without cells was subtracted from the readings
obtained on inserts with cells and this value was multi-
plied by the surface area of the insert (0.33 cm2).Monolayer permeability to Lucifer yellow/FITC-labelled
dextrans and calculation of permeability coefficients.
Lucifer yellow (LY) and FITC-labelled dextran stock
solutions were prepared in Ringers-HEPES buffer(150 mM NaCl, 3.4 mM CaCl2, 1.2 mM MgCl2, 5.2 mM
KCl, 0.5 mM NaHCO3, 2.8 mM glucose, and 10 mM
HEPES) and frozen at −20°C. RBECs were passaged
onto cell culture inserts as described and cultured for a
further 7–14 days in vitro. For transport experiments,
all media was removed from the upper chamber of the
insert and replaced with 75 μL pre-warmed Ringers-
HEPES buffer plus 0.1% BSA followed by equilibration
to 37°C for 10–15 minutes. Solutions of LY and FITC-
labelled dextran were diluted to 2X working concen-
trations and pre-warmed to 37°C. At time-point 0 mi-
nutes, 75 μL of LY/FITC-labelled dextran solution was
added to the upper chamber of the inserts, which were
then transferred to new 24-well plates containing 1 mL
of pre-warmed Ringers-HEPES buffer plus 0.1% BSA.
For each compound, inserts with endothelial cells were
used in triplicate and cell-free, collagen I/fibronectin-
coated inserts were used in duplicate. The plates were
incubated in an orbital shaking incubator (VWR) at
37°C, 25 rpm. At each time-point, the inserts were
moved into a fresh 24-well plate containing 1 mL of
pre-warmed Ringers-HEPES buffer plus 0.1% BSA, to
prevent back-diffusion of the compounds into the top
chamber. Samples were collected at 30, 60 and 90 mi-
nutes. At the end of each experiment, the concentra-
tion of the fluorescent compounds accumulated in the
bottom chamber was calculated by transferring 50 μL
of each sample to a black walled-96 well plate (Nunc)
and measuring with an Envision fluorescence plate
reader (Perkin Elmer). Concentrations were calculated
using standard curves generated from the stock solu-
tions of each compound. Permeability coefficients (Pe),
that take into account the barrier to transport from
both the endothelial monolayer and the cell culture
insert, were calculated as described by others [11,31,67,68].
Briefly, the volume cleared across cell-free and cell-
containing inserts was calculated for each compound using
the following equation:
Cleared volume μLð Þ ¼ Concentrationabluminal  Volumeabluminal
Concentrationluminal
The average cleared volumes were plotted versus time
in minutes for each 90-minute experiment. Clearance
slopes for the empty filters (PSfilter) and the filters with
endothelial cells (PScells + filter) were calculated using lin-
ear regression analysis and used to obtain a permeability








Permeability coefficients (Pe) for each compound
across the cell monolayer were finally derived by divid-
ing the PScells value by the surface area of the cell culture
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with units of × 10-6 cm/sec.
Assessment of claudin-5 protein levels by Western
blotting
RBECs were passaged into two 35 mm dishes, one
with RBEC/MVGS formulation media and one with
EBM-2/EGM-2 formulation media. The cells were cul-
tured to confluence and then lysed on ice by the
addition of RIPA buffer (Sigma) with protease inhibi-
tors followed by scraping. The levels of claudin-5 pro-
tein present in 10 μg total soluble protein were
assessed by SDS-PAGE and Western blotting using the
mouse anti-claudin-5 antibody (at 1:500; 1 μg/mL) also
used for immunocytochemistry (Table 1). The mem-
branes were re-probed using a mouse monoclonal anti-
body (ACTN05 (C4), Abcam, 1:2000). Western blots
were imaged using a Li-Cor Odyssey CLx and quantifi-
cation of band intensity was carried out using the
Li-Cor software.
Immunocytochemistry
Immunocytochemistry was performed on RBECs and
RSCECs cultured on collagen I/fibronectin coated 96-
well plates. Cells were cultured to confluence and
maintained for a further two days. Cultures were fixed in
either ice-cold methanol for two minutes (antibodies for
tight junction protein staining) or in 3.7% formaldehyde
for 20 minutes at room temperature (all other anti-
bodies). Formaldehyde-fixed cells were permeabilised
with 0.2% Triton X-100 in PBS for five minutes. After
rinsing once in PBS, cells were blocked in 5% BSA in
PBS for 30 minutes. All antibodies were diluted to work-
ing concentration in 1% BSA in PBS (Table 1). Cells
were incubated with primary antibody for 1 hour at
room temperature or overnight at 4°C, followed by three
5 minute washes in PBS. Secondary antibodies (Alexa
Fluor 488 donkey anti-goat IgG, Alexa Fluor 488 goat
anti-mouse IgG, Alexa Fluor 546 goat anti-mouse IgG,
Alexa Fluor 488 goat anti-rabbit IgG, Alexa Fluor 546Table 1 Antibodies used for immunocytochemical characteris
Antigen Species
Caveolin 1 Rabbit




Smooth muscle actin Mouse
Von Willebrand factor Rabbit
ZO-1 Rabbitdonkey anti-rabbit IgG; all from Life Technologies, Mo-
lecular Probes) were used at a final concentration of
2 μg/mL. Cells were incubated with secondary antibody
for 1 hour at room temperature followed by three
5 minute washes in PBS. Cells were finally counter-
stained with Hoechst (Life Technologies, Molecular
Probes), diluted to 1 μg/mL in 1% BSA/PBS, for one
minute and rinsed a further three times in PBS. Sam-
ples were imaged using an Olympus IX81 fluorescence
microscope.
Analysis of small molecule permeability using liquid
chromatography/mass spectrometry
Small molecule compounds were dissolved in DMSO to
a concentration of 1 mM and further diluted in Ringers-
HEPES buffer (without BSA) to give a final concentra-
tion of 4 μM. RBECs and RSCECs were passaged onto
cell culture inserts as described and cultured for a fur-
ther 7–14 days in vitro. Cell culture medium (EBM-2/
EGM-2 formulation) was removed from the upper and
lower compartments of RBECs and RSCECs cultured in
triplicate on cell culture inserts and duplicate cell-free
inserts and replaced with Ringer-HEPES buffer
(without BSA). The small molecules were added to each
upper compartment to yield a final concentration of
2 μM. Cultures were incubated at 37°C with shaking
and transferred to a new well with fresh buffer in the
lower compartment after 30, 60 and 90 minutes. Sam-
ples were collected from the lower compartments and
analysed by liquid chromatography mass spectrometry
(LC-MS/MS). Small molecules were analysed on an
Acquity™ UPLC system with an Acquity UPLC® BEH C18,
1.7 μm column (Waters Corp., Milford, MA, USA). 10 μL
of each sample was injected onto the column and eluted
by gradients. The flow rate was 0.6 mL/min and the
run time was 1.1 min. The Acquity™ UPLC-system was
connected to a triple quadrupole tandem mass spectrom-
eter (Quattro Premier XE, Waters Corp., Milford, MA,
USA) operating in the positive ion electrospray ionisation
mode, with MassLynx 4.1 running in the MRM modeation of cultured RBECs and RSCECs
Manufacturer Concentration
Abcam ab2910 20 μg/ml
Abcam ab21679 20 μg/ml
Life Technologies 35-2500 10 μg/ml
Life Technologies 33-1500 10 μg/ml
Abcam ab3366 3.35 μg/ml
R & D Systems MAB1420 4 μg/ml
Abcam ab6994 156 μg/ml
Abcam ab59720 10 μg/ml
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P-gp functional efflux assay
RBECs and RSCECs were passaged onto cell culture
inserts as described and cultured for a further 7–14 days
in vitro. Cell culture medium (EBM-2/EGM-2 formula-
tion) was removed from the upper and lower compart-
ments of RBECs and RSCECs cultured on cell culture
inserts in 24-well plates and was replaced with Ringers-
HEPES buffer with 0.1% BSA, containing either
100 μM verapamil or vehicle (0.5% DMSO), followed
by incubation at 37°C for 30 minutes. Cells were dye-
loaded by removing buffer from upper compartments
and replacing with fresh buffer containing 200 ng/ml
rhodamine 123. Triplicate cell culture inserts with cells
were used for each condition. The inserts were incu-
bated at 37°C for 30 minutes. The dye-loaded inserts
were transferred to a fresh plate and the buffer was re-
moved from the upper compartments. The cells were
washed three times in Ringer-HEPES buffer (with 0.1%
BSA). Fresh assay buffer was added and the inserts
were incubated at 37°C for 1 hour to allow dye efflux.
At the end of the incubation, the inserts were trans-
ferred to a fresh plate, the cells were washed three
times in PBS and lysed for 20 minutes in RIPA buffer.
Fluorescence values were measured for each sample
using an Envision multi-well fluorescence plate-reader
(Perkin Elmer) with excitation at 485 nm and emission
collected at 535 nm. Standard curves were generated
using stock rhodamine 123 and then used to calculate
cellular uptake of the dye.
Determination of FITC-dextran hydrodynamic radii by
dynamic light scattering
FITC-labelled dextrans (Sigma) were prepared at a con-
centration of 0.8 mg/mL in Ringers-HEPES buffer with-
out BSA. Samples were filtered through a 0.22 μm filter
prior to loading. Hydrodynamic radii were determined
using a Zetasizer Nano (Malvern). The backscatter of
light at 173° was measured with an equilibration time of
five minutes and measurements were performed in trip-
licate with no delay between them. Laser attenuation
and measurement duration were determined automatic-
ally by the software with data processing performed at
normal resolution.
Analysis and statistics
Standard curves were generated and sample concentra-
tions interpolated by linear regression using Microsoft
Excel. Statistical analysis, using the appropriate mathem-
atical functions as outlined in the text, was carried out
using GraphPad Prism. Values in figures are expressed
as mean ± SEM.Results
Isolation and culture of microvascular endothelial cells
from rat brain and spinal cord tissue
To establish a convenient cell culture system that gener-
ated a large yield of cells with minimum use of animal
tissue, microvascular endothelial cells were isolated from
the brain and spinal cord tissue of the same four rats.
We took the approach of plating isolated microvessels
into 6-well tissue culture dishes and allowing endothelial
cells to grow to near (>90%) confluence before passaging
on to cell culture inserts. To obtain the highest recovery
of microvessels, brain and spinal cord homogenates were
centrifuged through a 22% BSA gradient to obtain a vas-
culature pellet. We did not subject the brain and spinal
cord vasculature pellets to a size dependent filtration
step, as this resulted in the loss of some microvessel
fragments, thus decreasing the final yield of endothelial
cells. Following enzymatic digestion with collagenase/
dispase, brain and spinal cord vasculature fragments ex-
hibited typical “beads-on-string” appearance (Figure 2a, d)
as described by others [20]. We routinely cultured the
brain and spinal cord microvessel fragments in DMEM
with a commercially available microvascular growth sup-
plement (MVGS, Life Technologies) and 15% plasma-
derived serum (PDS), to minimise the PDGF-stimulated
growth of non-endothelial cells [31,61]. Upon plating,
microvessel fragments adhered to the extracellular matrix
coated dishes within 1–2 hours. The largest and most
branched sections of the vasculature did not adhere to
the plate and were easily removed during media chan-
ges. Under these conditions, rat brain endothelial cells
(RBECs) and rat spinal cord endothelial cells (RSCECs)
migrated out from the isolated fragments and prolife-
rated rapidly, reaching near confluence after 6–7 days
(Figures 1 and 2a-f). When culturing from four adult
rats into a 6-well plate format, a total of eight wells of
RBECs and two wells of RSCECs could be established,
ready for passage within 6–7 days (Figure 1). During the
initial plating phase, we adopted the technique of cul-
turing isolated microvessels in the presence of puromycin
to limit the growth of non-endothelial cells lacking ex-
pression of the P-gp efflux transporter [22,27,31,61,65].
Inspection of the RBEC and RSCEC cultures by phase
contrast microscopy indicated that they were near-pure
endothelial monolayers (Figure 2c, f ).
Passaging technique and characterisation of barrier
formation using rat blood–brain barrier endothelial cells
on cell culture inserts
Once brain and spinal cord endothelial cells could be re-
producibly isolated and cultured from the same rats, we
investigated passaging techniques onto cell culture inserts
and tissue culture dishes to utilise the large number of cells
generated. As more endothelial cells were obtained from
Figure 2 Isolation and culture of rat brain and spinal cord microvascular endothelial cells. Following BSA density centrifugation and
enzymatic digestion, isolated rat brain and spinal cord microvessel fragments were plated out onto collagen 1/fibronectin coated tissue culture
plates. On plating, (a) brain and (d) spinal cord microvessels exhibit a “beads-on-string” appearance with rounded endothelial cells present on the
surface (20× objective magnification). After 2–3 days in culture, (b) brain and (e) spinal cord endothelial cells are clearly visible migrating from the
microvessels onto the matrix-coated tissue culture dish (10× objective magnification). After 5–7 days in culture both (c) brain and (f) spinal cord
endothelial cells form a pure, near confluent monolayer (10× objective magnification).
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passaging and culture conditions using RBECs. Near con-
fluent monolayers of RBECs at 6–7 days in culture were
passaged with trypsin onto cell culture inserts. We found it
better to use a relatively high concentration of trypsin:
EDTA (0.25%) for a short amount of time (3–4 minutes),
rather than lower concentrations for a longer time period.
Milder passaging reagents, such as Accutase™ did not ef-
fectively remove the primary endothelial cells from the cul-
ture dish, nor break down junctions between cells. The
most likely reason for these observations was that the
endothelial cells already possessed strong intercellular
tight junctions. We thus trypsinised and dissociated the
primary monolayers to small clusters of approximately 5–10 endothelial cells. Confluent monolayers were not re-
producibly obtained when performing passages that di-
luted the cell suspension of RBECs 1:2 to 1:4-fold. We
were, however, able to obtain reproducible confluence
when the trypsinised RBEC cell suspension was trans-
ferred ~1:1 on a surface area basis; for example plating
one well from the 6-well plate into 25 cell culture inserts
in the 24-well format (Figure 1). This passaging method
allowed quick coverage of the surface area of the insert,
and the cells were able to reproducibly form barriers.
We investigated whether commercially available speci-
ality endothelial cell culture reagents could influence
both the quantity of endothelial cells recovered and the
quality of the rat in vitro barriers generated by this
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with MVGS supplement, we passaged the RBECs onto
collagen I/fibronectin-coated cell culture inserts and
compared two media formulations in both the top well
and bottom well: (a) DMEM with MVGS, and (b) EBM-
2 microvascular endothelial cell media with the EGM-2Figure 3 Effect of media composition on RBEC barrier formation and
EBM-2/EGM-2 media formulations on the TEER of RBECs grown for 14 days
analysed using an unpaired, two-tailed students t-test, ***P < 0.0001; n = 5
per experiment, equivalent to 15 inserts total . (b) Calculated permeability
yellow over a 90 minute period at 37°C across RBEC monolayers on cell cu
formulations. Data is presented as mean ± SEM and was analysed using an
cell culture experiments, with 3 inserts per experiment, equivalent to 15 ins
antibody raised against the tight junction protein claudin-5 following cultu
indicate regions of discontinuous claudin-5 staining. Images are representa
individual preparation of cells using the 20× objective on an Olympus IX81
levels in RBECs cultured in DMEM/MVGS and EBM-2/EGM-2. Blots were rep
lysates. (f) Densitometry analysis of claudin-5 band intensity, normalised to
presented as mean ± SEM and was analysed using an unpaired, two-tailedBulletKit without VEGF (Lonza). The endothelial cells
were co-cultured with mixed glia plated into the bottom
chamber of the dish, as the role of astrocytes in inducing
barrier phenotype in primary brain endothelial cells
in vitro is well validated [7,42,69,70]. We quantified barrier
phenotype by two standard methods; TEER, measured atcharacteristics. (a) Comparison of the effects of the DMEM/MVGS and
on cell culture inserts. Data is presented as mean ± SEM and was
independent cell culture experiments in 24-well plates, with 3 inserts
coefficients for the paracellular passage of 100 μM (50 μg/mL) Lucifer
lture inserts cultured in DMEM/MVGS and EBM-2/EGM-2 media
unpaired, two-tailed students t-test, ***P < 0.0001; n = 5 independent
erts total. Fluorescence microscope images of RBECs stained with an
re in (c) DMEM/MVGS supplement, or (d) EBM-2/EGM-2. White arrows
tive of 3 independent cultures, with five fields of view taken from each
microscope. (e) Western blot analysis of claudin-5 protein expression
robed with anti-actin antibodies as a control for equal loading of cell
actin levels, for RBECs grown in DMEM/MVGS vs. EBM-2/EGM-2. Data is
students t-test, *P < 0.01; n = 3 independent experiments.
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yellow over 90 minutes. When measuring TEER, we took
the approach of removing the cells from the incubator and
allowing them to equilibrate to room temperature. This
technique allowed greater consistency in TEER readings
when measuring with the commonly-used STX2 chop-
stick electrodes. Measuring large numbers of inserts dir-
ectly after removal from the incubator resulted in errone-
ous measurements due to media buffering when moving
from the regulated temperature and CO2 of a tissue culture
incubator. When removing inserts and measuring resist-
ance immediately, we found that TEER rose steadily until a
stable level was reached after approximately 20 minutes.
Allowing TEER values to stabilise at room temperature in-
creased the accuracy and consistency of the measurements
when measuring a large number of inserts.
Both the DMEM/MVGS and EBM-2/EGM-2 media
formulations lead to the development of reproducibly
robust barriers after 14 days in culture (Figure 3a, b).
Average pre-experimental TEER values were significantly
higher for the RBECs cultured in the EBM-2/EGM-2
media when compared to the DMEM/MVGS formula-
tion, with average TEER values at room temperature of
529 ± 14 Ω × cm2 versus 90 ± 3.6 Ω × cm2 (Figure 3a).
Peak TEER values measured at room temperature
in this experiment were as high as 802 Ω × cm2 in EBM-
2/EGM-2, versus 252 Ω × cm2 for the DMEM/MVGS
formulation. In agreement with the TEER data, small
molecule permeability for the same cell cultures was sig-
nificantly decreased for the passaged RBECs cultured in
EBM-2/EGM-2 media, with permeability coefficients
averaging 2.9 ± 0.26 × 10-6 cm/sec compared to 8.6 ±
0.76 × 10-6 cm/sec for DMEM/MVGS (Figure 3b). To
explore the effect of the two media conditions on tight
junction formation we immunostained cells grown on
cell culture inserts with an antibody raised against
claudin-5, a protein whose role in establishing restrictive
barrier phenotype in brain endothelial cells is well docu-
mented in vivo and in vitro [71-73]. The RBECs grown in
DMEM/MVGS showed localisation of claudin-5 around
the periphery of the cells, indicating intercellular tight
junction formation (Figure 3c). Under these conditions
however, several areas of discontinuous staining were also
observed, indicating potentially “leaky” gaps in the endo-
thelial tight junctions (Figure 3c). RBECs grown in the
EBM-2/EGM-2 media formulation however, showed in-
creased cell density and continuous claudin-5 staining at
the cell periphery, suggesting the formation of highly
organised, continuous tight junctions (Figure 3d). Western
blot analysis of cell lysates prepared from RBECs cultured
in the two different conditions, demonstrated that the
overall expression of claudin-5 was significantly increased
in the EBM-2/EGM-2 conditions, with a 2.4-fold increase
in protein levels (Figure 3e, f), The difference in claudin-5expression and localisation at tight junctions observed be-
tween cells cultured in the two media formulations may
contribute to the higher TEER and lower Pe to LY ob-
served when culturing RBECs in EBM-2/EGM-2. Culturing
passaged primary RBECs in the endothelial EBM-2/EGM-2
media combination thus significantly improved the quality
of the barrier phenotype developed by these high yield cell
cultures.
We further characterised RBEC barrier function in the
optimal EBM-2/EGM-2 culture conditions. TEER values in
the optimised media reached a maximum at 10 days in cul-
ture and remained at this level for several days, indicating
the persistent formation of continuous tight junctions
(Figure 4a). Furthermore, for RBECs passaged onto cell
culture inserts in the optimised conditions, a strong cor-
relative relationship was observed between the pre-ex-
perimental TEER values and subsequent permeability to
Lucifer yellow (Figure 4b). This relationship fitted an expo-
nential decay curve (R2 = 0.78), indicating that as TEER de-
creased, Pe to LY markedly increased. The exponential
decay curve reached plateau at an equivalent Pe to LY of
2.7 × 10-6 cm/sec. Such an exponential relationship in
endothelial permeability is in accordance with previously
described data in primary brain endothelial cells from
other species [74] and in brain endothelial cell lines [75].
We next characterised RBEC barrier permeability to
larger molecules that non-specifically cross the mono-
layer by paracellular diffusion. RBECs cultured on cell
culture inserts in EBM-2/EGM-2 media were used to
measure the permeability coefficients for FITC-labelled
dextrans of increasing size (Figure 4c). The observed Pe
value for transport of each FITC-labelled dextran mol-
ecule was plotted versus its hydrodynamic radius (HR)
(Figure 4c). When performing such experiments it is
more accurate to use the HR of a molecule rather than
its molecular weight. Molecules of the same weight can
have different HR and diffusion profiles in solution due
to their shape (e.g. rod-like FITC- labelled dextrans ver-
sus spherical globular proteins). To obtain accurate
hydrodynamic radii for the FITC-labelled dextrans used,
we analysed each molecule using dynamic light scatter-
ing (DLS, Table 2). When permeability was plotted ver-
sus HR, a strong relationship between the two was
observed, which fitted to an exponential decay curve
(R2 = 0.86, Figure 4c). The smaller molecules showed the
highest non-specific paracellular permeability, and per-
meability reached plateau at Pe = 0.09 × 10-6 cm/sec, cor-
responding to molecules with a hydrodynamic radius of
4.5 nm (i.e. 40 kDa FITC-dextran) and above.
Characterisation of barrier-related protein expression in
rat brain endothelial cells cultured in EBM-2/EGM-2 media
Having established that the most reproducible and robust
RBEC barrier phenotypes were induced by co-culture in
Figure 4 Characterisation of RBEC monolayer barrier function
induced by co-culture in optimised EBM-2/EGM-2 media. (a)
Development and stabilisation of TEER for passaged RBECs grown on cell
culture inserts in the optimised EBM-2/EGM-2 conditions over a two week
period. TEER was measured following equilibration of the inserts in cell
culture medium to room temperature, n = 5 independent cell culture
experiments. (b) Relationship between pre-experimental TEER and
permeability to Lucifer yellow over 90 minutes at 37°C in the EBM-2/EGM-
2 media conditions. Data was fitted to a one-phase exponential decay
curve, R2 = 0.78, n = 6 independent cell culture experiments, equivalent to
71 inserts in total. Peak TEER at room temperature in this experiment
reached as high as 999 Ω× cm2. (c) Permeability of Lucifer yellow (50 μg/
mL) and FITC-labelled dextrans (10 mg/mL) of increasing hydrodynamic
radius across RBEC monolayers in the optimised
EBM-2/EGM-2 media conditions. Pe was calculated over a 90 minute
time-course and was plotted versus the hydrodynamic radius of each
molecule. Data was fitted to a one-phase exponential decay curve, R2 =
0.86, n = 2 independent cell culture experiments, equivalent to 6 inserts in
total for each molecule tested.
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characterisation of the cells using immunocytochemistry
(Table 1, Figure 5). The passaged RBEC monolayers were
found to be essentially purely endothelial in nature as
judged by antibody staining with the endothelial marker
von Willebrand factor (vWF, Figure 5a). There were no
non-endothelial cells disrupting the monolayer and any
such cells present in the passaged cultures were most likely
to be smooth muscle actin (SMA)-positive pericytes sitting
on top of the endothelial monolayer without perturbing
its confluence (Figure 5b). Staining with antibodies
recognising the tight junction markers claudin-5, ZO-1
and occludin, all well-known to be required for BBB func-
tion, showed the presence of continuous and well-
organised tight junctions between cells in the endothelial
monolayers (Figure 5c, d, e). Some diffuse cytoplasmic
staining of claudin-5 and ZO-1 was observed, but all endo-
thelial cells presented highly organised tight junction stain-
ing without gaps or frayed edges. We also investigated two
major endocytic/transcytotic pathways in the cultured
RBECs by performing immunocytochemistry with anti-
bodies specific for clathrin and caveolin-1. RBECs showed
strong immunoreactivity for both clathrin (Figure 5f) and
caveolin (Figure 5g). Caveolin-1 was distributed evenly
and densely throughout the cytoplasm of the RBECs, with
individual puncta difficult to observe. In contrast, clathrin
staining was more punctuate in nature, with most RBECs
showing a distinct concentration of clathrin-positive
puncta in a peri-nuclear location. Staining with antibodies
raised against the P-gp efflux transporter, revealed expres-
sion of this important transporter in the cultured RBECs
(Figure 5h). These immunocytochemistry data thus
support our previous observations of a tight barrier
phenotype of pure endothelial cells with limited para-
cellular permeability.
Establishment and characterisation of rat blood-spinal
cord endothelial in vitro barriers
Having successfully established a protocol for passaging
RBECs to increase the cell yield and induce reproducibly
tight barrier phenotypes, we analysed whether the
optimised EBM-2/EGM-2 media would have similar ef-
fects on the endothelial cells that were isolated from rat
spinal cord (Figure 1). We isolated and cultured primary
RSCECs and passaged the cells in a similar manner to
the RBECs, splitting at a ~1:1 transfer ratio onto cell
culture inserts. The passaged RSCECs were then cul-
tured in the presence of pre-seeded mixed glia in 24-
well plate format, using the EBM-2/EGM-2 media
formulation supplemented with 15% PDS. The RSCECs
exhibited tight barrier characteristics with average pre-
experimental TEER values of 293 ± 43 Ω × cm2 and Pe to
LY of 3.8 ±0.67 × 10-6 cm/sec (Table 3). Individual pre-
experimental TEER values at room temperature reached
Table 2 Experimentally determined hydrodynamic radii and observed permeability coefficients across RBEC
monolayers for Lucifer yellow and FITC-dextrans
Molecule Molecular
weight (kDa)
Hydrodynamic radius (nm) Mean paracellular transport (× 10-6 cm/sec) SEM (× 10-6 cm/sec)
Lucifer Yellow 0.5 0.49 2.22 0.137
4 kDa FITC-Dextran 4 1.40 1.00 0.201
10 kDa FITC-Dextran 10 2.30 0.46 0.117
20 kDa FITC-Dextran 20 3.30 0.38 0.142
40 kDa FITC-Dextran 40 4.50 0.16 0.038
70 kDa FITC-Dextran 70 6.00 0.14 0.049
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as 1.02 × 10-6 cm/sec. Much like the barriers formed by the
passaged RBECS in the optimised media conditions, the
RSCECs showed an exponential decay relationship be-
tween the pre-experimental TEER value recorded at room
temperature and the permeability to Lucifer yellow
(Figure 6, R2 = 0.91). The exponential decay curve reached
plateau at an equivalent Pe to LY of 0.28 × 10-6 cm/sec.
Thus, although the RSCECs did not reach overall pre-
experimental TEER values as high as those observed for
cultured RBECS in the optimised culture conditions, they
showed similarly low paracellular permeability to small
molecules such as LY.
The passaged RSCECs were then cultured in the
optimised EBM-2/EGM-2 media conditions and
characterised by immunocytochemistry, using the same
panel of antibodies as for the RBEC characterisation
(Table 1, Figure 7). Similar to the RBEC cultures, the
RSCECs were found to be essentially pure preparations
of endothelial cells, exhibiting uniform staining with an
antibody raised against the endothelial marker vWF
(Figure 7a). Only isolated cells on top of the continuous
monolayer stained positive for the non-endothelial marker
SMA, making up less than 1% of the cultures (Figure 7b).
The RSCECs exhibited highly organised tight junctions
and claudin-5, occludin and ZO-1 were all detected with
discrete, continuous localisation around the periphery of
the endothelial cells with no frayed edges (Figure 7c, d
and e). Immunostaining with antibodies raised against
clathrin and caveolin-1 demonstrated that the RSCECs
expressed these proteins in a similar pattern to the RBECs
(Figure 7f, g). Caveolin-1 was detected throughout the cell
cytoplasm, stopping just short of the cell edges, whereas
clathrin was more punctuate and concentrated in a peri-
nuclear region. These results indicate that the cultured
RSCECs have the relevant protein machinery in place for
two of the major endocytic and trafficking pathways in
endothelial cells when cultured in vitro. Expression of
P-pg efflux transporter was also confirmed in the cultured
RSCEC cells (Figure 7h). Our observations thus demon-
strate that pure RSCECs co-cultured in the optimised
EBM-2/EGM-2 media conditions showed tight barrierfunction and expression of endothelial markers, tight junc-
tion proteins, endocytosis machinery and P-gp efflux
transporter when cultured in vitro.
Utility of optimised RBEC and RSCEC monolayers for small
molecule drug discovery
We next investigated the utility of the passaged RBEC and
RSCEC monolayers for small molecule drug discovery pur-
poses. To this end we analysed whether the optimised
endothelial cells from rat brain and spinal cord exhibited
functional P-gp efflux transporter activity and formed bar-
riers that were discriminating to passage of small molecule
compounds known to be excluded from the CNS paren-
chyma in vivo. To investigate the functionality of P-gp ef-
flux transporter in the RBEC and RSCEC in vitro models
we analysed the intracellular accumulation of rhodamine
123 in cells cultured on cell culture inserts. Rhodamine
123 is a fluorescent P-gp substrate which is actively
effluxed from cells that express this clinically important
transporter. Active efflux of rhodamine 123 can be reduced
by treatment with the P-gp inhibitor verapamil, resulting
in the accumulation of fluorescence within the cell. The
RBEC and RSCEC monolayers both demonstrated negli-
gible accumulation of rhodamine 123 when treated with
DMSO vehicle (Figure 8a, b). Both cell types showed basal
uptake of less than 0.1% of the initial input rhodamine 123
concentration. Pre-treatment of the cultured RBECs and
RSCECs with 100 μM verapamil resulted in a significant
increase in rhodamine 123 accumulation in both cell types
(Figure 8a, b). Cellular uptake of rhodamine 123 increased
to 0.88 ± 0.33% and 0.89 ± 0.27% for RBECs and RSCECs
respectively. These observations indicate that P-gp efflux
transporter is functional in RBEC and RSCECs co-cultured
with mixed glia in the EBM-2/EGM-2 media formulation.
We next investigated whether the in vitro RBEC and
RSCEC barriers were effective at preventing the passive
permeability of small molecules known to be excluded
from the CNS by the BBB and BSCB in vivo. Tight
in vitro barriers are critical for such experiments, redu-
cing paracellular permeability of small molecules which
would otherwise lead to misleading estimates of passive
permeability. We chose a panel of lipophilic small
Figure 5 Characterisation of BBB protein expression in cultured RBECs by immunocytochemistry. Images show fixed and permeabilised
RBECs cells grown on collagen I and fibronectin-coated 96-well plates and stained with antibodies for (a) von Willebrand Factor, (b) smooth
muscle actin, (c) claudin-5, (d) ZO-1, (e) occludin, (f) clathrin heavy chain, (g) caveolin-1, (h) P-gp. Images are representative of 3 independent
cultures, with five fields of view taken from each individual preparation of cells using the 20× objective [10× for 5 (b) for a wider field of view] on
an Olympus IX81 microscope.
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fusion in vivo (propanolol, caffeine, hydroxyzine and ris-
peridone) and a panel of molecules with poor passive
permeability characteristics that do not easily cross intothe CNS in vivo (atenolol, methotrexate and sulpiride).
Both the RBECs and the RSCECs had excellent discrim-
inatory characteristics and excluded the poorly perme-
able molecules whilst allowing passage of the more
Table 3 Comparison of the in vitro barrier tightness of RBEC and RSCEC monolayers cultured on Millipore cell culture
inserts
Ave. pre-experimental TEER ±
SEM (Ohms × cm2)
Ave Pe to LY ±
SEM (cm/sec)
Maximum observed
pre-experimental TEER (Ohms × cm2)
Lowest Pe to
LY (cm/sec)
R2 (TEER vs. Pe to LY)
RBEC 529 ± 14 2.9 ± 0.26 × 10-6 999 1.4 × 10-6 0.78
RSCEC 293 ± 0.26 3.8 ± 0.67 × 10-6 722 1.04 × 10-6 0.91
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Table 4). For the RBEC monolayer, the CNS penetrant
molecules showed permeability coefficient values ran-
ging from 143 to 394 × 10-6 cm/sec, with the poorly
permeable compounds showing values 3.37 to 26.4 ×
10-6 cm/sec. The CNS-crossing molecules showed per-
meability values of 184 to 376 × 10-6 cm/sec across the
RSCEC monolayers, whilst the poorly permeable drugs
showed values as low as 1.73 to 10.3 × 10-6 cm/sec. Thus
the endothelial barriers formed by both RBECs and
BSCB in the optimized EBM-2/EGM-2 culture condi-
tions show excellent discriminatory characteristics that
accurately predicted the permeability of CNS-crossing
and impermeable small molecule drugs in vitro.
Discussion
The development and improvement of in vitro models of
the blood-CNS barriers is an ongoing effort towards both
understanding the biology of these important regulatory
tissues, and being able to overcome the formidable obstacle
that they present to the delivery of therapeutics for the
treatment of debilitating neurological diseases. Human, rat
and mouse BBB cell lines have been developed but, al-
though cheap and convenient to use, these cells produce
barriers with high intrinsic paracellular permeabilityFigure 6 Barrier function demonstrated by RSCEC monolayers
co-cultured on cell culture inserts with mixed glial cells.
Relationship between pre-experimental TEER, measured at room
temperature, and permeability to Lucifer yellow over 90 minutes at
37°C in the optimised EBM-2/EGM-2 media conditions. Data was
fitted to a one-phase exponential decay curve, R2 = 0.91, n = 8
independent cell culture experiments, 24 cell culture inserts in total.making them poorly-suited for applications such as drug
transport screening and characterisation [5,76-78]. Due to
this fact, in vitro primary cell models of highly differenti-
ated endothelial cells from the BBB and BSCB remain a
critical tool for investigative and pharmaceutical biology,
particularly in the species typically used in pre-clinical
studies. Such in vitro primary models have been utilised
for genomics and proteomics studies [30,79-81], analysing
endothelial transporter function [15,16,65,82,83], studying
brain metastasis of cancer cells [84], and applied to transla-
tional pharmaceutical studies, investigating small molecule
drug transport [77,85,86] and toxicity [67,87].
Here, we describe a further development in techniques
producing such in vitro barrier models from primary rat
CNS tissue, providing the first description of the provision
of both brain and spinal cord endothelial cells from the rat,
a species of pre-clinical importance in pharmaceutical
CNS drug development and a commonly used laboratory
model organism. High yields of differentiated cells are cul-
tured from the same donor animals, reducing cost, labour
and number of animals required. Furthermore, the endo-
thelial cells obtained by this method are able to form
monolayers with excellent barrier characteristics in vitro,
making them suitable for use in biological investigations
and in drug transport and toxicity studies. Importantly, our
methods detail the first procedure for the culture of robust
and in vivo-like spinal cord endothelial cells from the rat,
complementing existing descriptions from mouse [55], and
we also provide the first description of a functional in vitro
barrier phenotype for spinal cord endothelial cells from
any species.
Our aim was to achieve high yields of RBECs and
RSCECs to provide a large number of cells that could
be used for biological studies and drug discovery. We
therefore introduced steps into our protocol to facili-
tate enhanced recovery of endothelial cells. Firstly, to
increase cell numbers, we omitted size-dependent fil-
tration from our microvessel isolation protocol. Filter-
ing the microvessels enriches for smaller capillaries,
which are hypothesised to be more “BBB-like” [88], but
decreases the overall yield of endothelial cells. By filter-
ing through 40 μm or 70 μm cell strainers, we observed
that many microvessels of a wide range of sizes, includ-
ing small capillaries, were retained on the cell strainer.
We thus plated out the whole microvessel pellet iso-
lated by BSA density centrifugation and subjected it to
puromycin purification [27,31,51,61,65]. In addition to
Figure 7 Characterisation of cultured RSCECs by immunocytochemistry. Images show fixed and permeabilised RSCECs cells grown on
collagen I and fibronectin-coated 96-well plates and stained with (a) von Willebrand Factor, (b) smooth muscle actin and vWF, (c) claudin-5,
(d) ZO-1, (e) occludin, (f) clathrin heavy chain, (g) caveolin, (h) P-gp. Images are representative of 3 independent cultures, with five fields of view
taken from each individual preparation of cells using the 20× objective [10× for 7(b) for a wider field of view] on an Olympus IX81 microscope.
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selective pressure on the endothelial cells; RBECs
and RSCECs with high expression of P-gp, a charac-
teristic of in vivo blood-CNS barriers, are able to sur-
vive and proliferate in vitro. Indeed our data indicatesthat both RBECs and RSCECs in culture express P-gp
efflux transporters (Figures 5h and 7h) that retain func-
tionality (Figure 8a, b). By culturing cells using this se-
lective method, we obtained large numbers of primary
endothelial cells, which were then passaged onto cell
Figure 8 Characterisation of optimised RBEC and RSCEC barriers for use in small molecules drug studies. Intracellular accumulation of the
fluorescent P-gp efflux transporter substrate rhodamine 123 in (a) RBECs (n = 4) and (b) RSCECs (n = 3) cultured on cell culture inserts in the absence
and presence of the inhibitor verapamil. Data is presented as mean ± SEM and was analysed using an unpaired, two-tailed students t-test, *P < 0.01,
**P < 0.001. Permeability coefficients for CNS-permeable and impermeable small molecule drugs were calculated across (c) RBEC (n = 5 independent
cell culture experiments) and (d) RSCEC monolayers cultured on cell culture inserts (n = 3 independent cell culture experiments).
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highly-differentiated barrier phenotype.
We next looked to improve reproducibility in obtaining
tight barriers, as a lack of robustness is a common problem
when culturing primary brain endothelial cells in vitro.
Our observations from passaging brain endothelial cells
led us to an approach of splitting cells on the basis of the
surface areas of the receiving culture dishes, rather than byTable 4 Permeability of CNS and non-CNS crossing small mol








Atenolol No 15 16.53
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Hydroxyzine Yes 8 234.3
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Methotrexate No 15 24.26
Propanolol Yes 15 198.8
Risperidone Yes 11 143.1
Sulpiride No 15 26.41traditional dilution splitting on the basis of cell numbers. If
RBECs or RSCECs were transferred to new dishes or cell
culture inserts as a dilution passage (e.g. splitting 1:4–1:2)
they frequently grew as islands of cells which stopped pro-
liferating and did not form a continuous monolayer, ren-
dering them unsuitable for barrier studies on cell culture
inserts. If, however, the cells were transferred on the basis
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(Figure 1). Thus, a key element of our protocol is the con-
cept of the ~1:1 passage of endothelial cells. This transfer
method facilitated excellent barrier phenotypes for both
RBECS and RSCECs (Figures 3, 4 and 6), with no obvious
endothelial de-differentiation as judged by immunocyto-
chemistry which demonstrated well organised, mature
tight junctions and expression of endocytic transport ma-
chinery (Figures 5 and 7). Furthermore, the technique reli-
ably resulted in the provision of useable barriers in almost
every insert. We observed very low losses of individual in-
serts where barriers did not form, as often happened with
dilution passaging. Individual inserts where the barrier
failed were usually found to be due to handling technique
and mechanical damage to the monolayer.
A major finding of our study was that barriers with
high TEER and low Pe to small molecules such as LY
were reproducibly obtained when culturing RBECs and
RSCECs in Lonza’s EBM-2 basal medium with the
EGM-2 BulletKit minus VEGF. The Lonza BulletKit con-
tains supplements, such as hydrocortisone and FGF, that
are well validated to improve endothelial barrier func-
tion in vitro [22,61]. This EBM-2/EGM-2 media combin-
ation outperformed DMEM supplemented with another
commercial supplement, MVGS. The optimised condi-
tions also included the addition of 15% plasma-derived
serum and the monolayers did not display the sensitivity
to serum-derived factors that has been observed in some
in vitro BBB cell culture models [52].
Historically, the BBB has been more highly studied
than the BSCB both in vivo and in vitro. An emerging
consensus is that the two are broadly similar with some
subtle differences, for example in their permeability and
their vulnerability to certain insults and diseases [4,89].
The BSCB has an almost identical physical structure to
that of the BBB, with tight junction-containing endothe-
lial cells surrounded by and interacting with astrocytes
and pericytes [89]. The BSCB also appears to be more
permeable than the BBB in certain sub-regions but is
still a tight and highly regulated barrier that protects the
spinal cord parenchyma. Studies in vivo have indicated
that the BSCB is more permeable than the BBB to small
tracers, cytokines and neurotrophins, with lumbar regions
of the spinal cord in particular being more permeable
[90-94]. Some cytokines and growth factors however, such
as IL-1α and granulocyte-macrophage colony-stimulating
factor (GMCSF), have been shown to have similar trans-
port across the BSCB as the BBB in vivo [95,96]. Other evi-
dence suggests that the BBB and BSCB have similarly low
permeability to large plasma proteins such as IgGs and al-
bumin [95,97]. Similarities between the BBB and BSCB
have also been noted in the expression and functionality of
ABC transporters, which are hypothesised to play key roles
in disease and drug resistance. Isolated capillaries frommouse brain and spinal cord show similar expression and
functionality of P-gp, MDR2 and BRCP [82,83]. ABC-
transporters at the BBB and BSCB also share similar in-
creased expression and functionality following exposure to
dioxins, and in mouse models of amyotropic lateral scler-
osis (ALS) in vivo [82,83]. Interestingly, our models show
that RSCEC monolayers are generally slightly more perme-
able than with RBECs, in spite of the fact that both are cul-
tured in the presence of glial cells derived from brain
tissue. Although data is lacking attesting to differences be-
tween brain and spinal cord astrocytes in their ability to in-
duce barrier phenotypes, our observations may indicate
that some aspects of the permeability properties of
RSCECs are cell-intrinsic.
The only previously published in vitro study compar-
ing BBB and BSCB cells was carried out using endothe-
lial cells derived from mouse [55]. In that study, culture
conditions for both endothelial cell types were
established and expression levels of proteins associated
with barrier function were characterised, although no
functional barrier data was presented. Ge and Pachter
(2006) found that cultured endothelial cells from both
type of CNS tissue were indistinguishable under the
microscope and showed identical expression of the
endothelial markers vWF and PECAM-1, as well as
similar uptake of LDL [55]. Our extensive characterisa-
tion data for endothelial markers, tight junction pro-
teins, endocytic machinery and the P-gp efflux
transporter, suggests a similar situation to be true for
brain and spinal cord endothelial cells from rat
(Figures 5 and 7). Additionally, Ge and Pachter provi-
ded a highly useful comparison of several genes impor-
tant for barrier function in these cultured endothelial
cells [55]. Gene expression of claudin-1, claudin-5,
P-gp and transferrin receptor were unchanged between
both types of endothelial cell in mouse, but expression
levels of ZO-1, occludin, β-catenin and VE-cadherin
were lower in spinal cord endothelial cells compared to
those from brain tissue [55]. This observation is in
agreement with in vivo descriptions of the BSCB being
more permeable than the BBB.
Our observations further support and extend these ob-
servations on the structure and function of the BBB and
the BSCB. We have shown that cells from both the rat
BBB and BSCB can be cultured on cell culture inserts
in vitro to form functionally restrictive cell monolayers,
with the endothelial cells of the brain forming slightly
tighter barriers than those of the spinal cord. In this re-
gard our in vitro models apparently mimic the in vivo
situation for the BBB and BSCB. We observed an excel-
lent relationship between pre-experimental TEER values
and Pe to LY in permeability assays for both models
(R2 = 0.78 for RBECs and 0.91 for RSCECs). Importantly,
this indicates that the pre-experimental TEER value is
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ducible experiments to be performed. Cell culture in-
serts with high TEER values can be selected from the
outset and matched with inserts of similar barrier tight-
ness, allowing robust experiments to be performed on
primary-derived cells that have similar intrinsic perme-
ability properties.
Our BBB and BSCB models exhibited excellent dis-
crimination characteristics for limiting the passage of
small and large molecules that cross the barrier by para-
cellular diffusion, such as LY and FITC-dextrans, and
also for small molecules that enter the CNS poorly on
the basis of their low lipophilicity. This makes our
models ideally suited for in vitro permeability studies,
particularly for small molecule drugs where tight in vitro
barriers are critically required to minimise non-specific
paracellular transport that would mask true permeability
characteristics and kinetics. Small molecule permeability
across an in vitro barrier has been demonstrated by sev-
eral groups using different species, including human,
porcine, mouse and rat, but only across endothelial
monolayers derived from cells of the BBB [16,25,54,65].
Our methods show that we are able generate a large
number of tight in vitro barriers representing the rat
BBB, but we also demonstrate for the first time an
in vitro model of rat spinal cord endothelial cells that
shows similar restrictive properties to small molecules.
These data suggest that our models would be suitable
for a broad range of CNS drug discovery studies, par-
ticularly for instances where a drug target is located
within the spinal cord as well as, or instead of, in the
brain. The RBEC and RSCEC barriers also show expres-
sion and functionality of the clinically important efflux
transport P-gp (Figures 5h, 7h and 8a, b). These BBB
and BSCB models could thus be used for in vitro studies
of barrier function involving this transporter, such as de-
termining the efflux of chemotherapeutic small molecule
drugs which are often also P-gp substrates.
Since differences between the BBB and BSCB exist, it
is therefore essential that in vitro models for both
barriers are available for research purposes. An in vitro
model for one barrier may not necessarily be an appro-
priate substitute for the other. This may be of particu-
lar relevance when studying diseases which affect one
CNS compartment more than the other [4,89]. Our
in vitro models of both types of blood-CNS barrier are
thus of great potential value for the investigation
of such disease processes. Since these models are
optimised for rat tissues, a species for which relevant
and well-characterised in vivo models of CNS-disease
exist, they have great potential utility in translational
studies. Our novel in vitro RSCEC model of the rat
BSCB may also contribute to the furthering of know-
ledge about this poorly-understood blood-CNS barrierand could be applied to genomics and proteomics stud-
ies in the future.
Conclusion
In conclusion, we have demonstrated an easy and ro-
bust method to prepare large yields of endothelial cells
from rat brain and spinal cord tissue. Our method has
the advantages of ease-of-use and reproducibility and
provides culture conditions suitable for the isolation
and culture of both RBECs and RSCECs as coincident
sister cultures. The high yields of cells obtained go
some way to overcoming the often limiting amount of
material available for experiments, a common problem
that is often encountered when performing studies with
primary cell models of the BBB and BSCB. The
optimised RBEC and RSCEC cultures show expression
of typical markers representative of the blood-CNS bar-
riers in vivo and form functional barriers in vitro that
are discriminating in preventing the passage of large
molecules and poorly lipophilic small molecule drugs.
The tight barrier phenotype obtained for both models
allows predictive drug permeability studies to be
performed, due to the low intrinsic non-specific para-
cellular permeability of the pure endothelial mono-
layers. We hope that these models will prove to be a
valuable addition to the tools available to academic and
industrial researchers for both drug discovery and
studying the biology of BBB and BSCB in an in vitro
setting.
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